This phase I trial will begin to understand how safe and tolerable an intravenous cancer drug (ABBV-467) is for the treatment of multiple myeloma in patients who have not responded or got worse on previous treatment.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A First In Human Study of the MCL-1 Inhibitor, ABBV-467
This trial contains two parts: dose escalation and dose expansion. Eligible patients will receive intravenous ABBV-467, either at a variable or recommended dose, depending on the part to which they are allocated.
Recruiting Hospitals Read More